Wegovy, Mounjaro maintain rapid upward trajectories

Aggregate quarterly revenue from the GLP-1 franchise of Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) rose to $6.1 billion in 3Q23, a 9% increase over last quarter and 73% higher than in 3Q22. Diabetes therapy Ozempic semaglutide and obesity drug Wegovy semaglutide made up 74% of that number, respectively accounting for $3.4 billion and $1.4 billion. 

Eli Lilly and Co. (NYSE:LLY) posted total 3Q23 GLP-1 sales of just under $3.1 billion, $1.4 billion of which came from Mounjaro tirzepatide. ...